We discover and develop revolutionary treatments for neurodegenerative diseases
Our Scientific Platform
Read about the science behind our approach to treating neurodegenerative diseases.
Our Pipeline
Our clinical development strategy focuses on the inhibition of pathological glial activation and its role in preventing neuronal cell death.
Neuraly in the News
March 27, 2023
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD).
April 19, 2022
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).
Jan 28, 2022
How the Prism Parkinson’s Research Study Might Change the Way We Treat Parkinson’s
Three times in history, the stars aligned to create an environment in which a Parkinson’s breakthrough therapy was possible.
The first was in 1960, when scientists first realized that dopamine was linked to Parkinson’s — a realization that helped researchers discover how levodopa could treat symptoms.